Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Roche

Tracked across 69 events · 1197 articles · First seen Apr 22, 2025 · Last active Sep 24, 2026

Sentiment
24
Attention
8
Events
69
Relationships
38
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 75
Tech
Impact: Roche launched its new AXELIOS 1 sequencing platform, which is expected to enhance its position in the genomics market and potentially drive future revenue growth.
Jun 29, 2026 · 7 articles
4 70
Business
Impact: Roche is expanding its global technology network by establishing a new Digital Technology Hub in India — Hyderabad to leverage India's talent pool and strengthen its digital healthcare solutions. This expansion is expected to accelerate innovation and improve operational efficiency for the company.
Jul 01, 2026 · 7 articles
6 75
Tech
Impact: As a leading healthcare company, Roche>>> developed a rapid PCR test for the Bundibugyo virus through its subsidiary Trends (journals)>>>, significantly contributing to global outbreak response efforts and enhancing its reputation in diagnostics.
Jun 04, 2026 · 8 articles
4 70
Regulatory
Impact: Roche's supplemental Biologics License Application for Atezolizumab has been accepted by the United States — Food and Drug Administration>>> for Priority Review, potentially leading to a new standard of care for stage III colon cancer and boosting its market position.
Jun 11, 2026 · 6 articles
4 70
Regulatory
Impact: Roche received IVDR approval for its VENTANA MMR RxDx Panel, expanding its use across multiple cancer types and therapies, which is a positive development for the company's diagnostics division and market position.
Jun 11, 2026 · 6 articles
8 85
Business
Impact: Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, strengthening its hematology portfolio and expanding into immunology and neurology. This deal positions Roche to potentially lead in the BTK degrader market.
Jun 07, 2026 · 22 articles
3 40
Business
Impact: Roche received CE Mark for its Elecsys IGRA TB test, expanding its diagnostics offering and potentially boosting sales in TB testing.
Jul 09, 2026 · 6 articles
2 20
Business
Impact: Roche introduced the cobas HDV test, expanding its diagnostics offering and reinforcing its leadership in automated molecular testing. The launch may drive incremental revenue and strengthen customer loyalty.
Jul 14, 2026 · 7 articles
2 60
Business
Impact: Roche is the main actor, launching new PCR tests to expand its cyclospora portfolio, reinforcing its position in infectious disease diagnostics and potentially boosting sales.
Aug 06, 2026 · 6 articles
4 80
Regulatory
Impact: Roche developed the test and received FDA clearance, expanding its Alzheimer's diagnostic portfolio and potentially increasing revenue from test sales and analyzer usage.
Aug 24, 2026 · 7 articles
4 70
Tech
The PrevenTron phase III clinical trial, led by United Kingdom — Cornwall Partnership NHS Foundation Trust in the UK, will test whether the experimental Alzheimer's drug trontinemab, developed by Roche, can prevent dementia in healthy…
Impact: Roche developed trontinemab and is sponsoring the PrevenTron trial. Positive trial results could position Roche as a leader in Alzheimer's prevention, potentially boosting its pipeline and stock.
Sep 04, 2026 · 6 articles
2 25
Regulatory
Roche announced on 10 September 2026 that the United States — Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application for Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein…
Impact: Roche is the sponsor of the Enspryng MOGAD filing and stands to gain a first-in-class label expansion if approved, reinforcing its neurology portfolio and offering incremental revenue from 2027.
Sep 09, 2026 · 6 articles
4 60
Business
Impact: The licensee acquires exclusive global rights to a promising tri-specific antibody, strengthening its oncology and immunology pipeline, though the financial impact depends on clinical success.
Jul 20, 2026 · 11 articles
4 70
Business
Impact: As a leading company in the CLIA market, Roche is strengthening its market position through innovation and strategic collaborations, with its cobas e series platforms playing a major role in advancing high-throughput immunodiagnostic testing globally.
Jun 05, 2026 · 6 articles
4 50
Business
Impact: Roche gains co-development and co-commercialization rights to bexobrutideg, a potential best-in-class BTK degrader, expanding its pipeline in oncology, immunology, and neurology.
Jul 21, 2026 · 6 articles
4 35
Tech
F. Hoffmann-La Roche — Genentech, a member of the Roche Group, and its partner Ionis Pharmaceuticals announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary…
Impact: Roche, as F. Hoffmann-La Roche — Genentech parent and licensor of sefaxersen from Ionis, stands to benefit from a potential new IgAN therapy that could add to its kidney disease franchise.
Sep 23, 2026 · 6 articles
6 60
Tech
Impact: As the parent company of F. Hoffmann-La Roche — Genentech, Roche benefits from the positive clinical trial results of enicepatide and petrelintide, which enhance its overall pharmaceutical pipeline and potential for future revenue in the obesity and diabetes markets.
May 27, 2026 · 19 articles
2 40
Business
Impact: Roche is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
4 50
Tech
Impact: Roche collaborates with Nurix on bexobrutideg development and co-commercialization in the US; the trial strengthens its oncology pipeline.
Aug 04, 2026 · 6 articles
2 20
Business
Impact: Roche, as parent company, is investing in the facility as part of its $50 billion U.S. commitment, enhancing its manufacturing network and long-term growth prospects.
Aug 18, 2026 · 6 articles
4 70
Business
Impact: As the parent of F. Hoffmann-La Roche — Genentech, Roche strengthens its cardiometabolic portfolio, aligning with its strategy to address obesity and related conditions.
Jul 20, 2026 · 7 articles
4 60
Tech
Impact: Roche Ltd. is recognized as a top company in the epigenetics market, indicating its significant role and potential to benefit from market expansion.
Jun 26, 2026 · 6 articles
6 60
Tech
Impact: As the parent company of F. Hoffmann-La Roche — Genentech>>>, Roche>>> benefits from the positive developments regarding giredestrant's regulatory progress and its potential market impact.
Jun 02, 2026 · 6 articles
1 55
Business
Impact: Major diagnostics provider; growth forecasts favorable.
Jul 08, 2026 · 6 articles
2 5
Regulatory
Chairs of nine European pharmaceutical companies published an open letter on their corporate websites on September 22, 2026, calling on the European Union and its member states to boost investment in the region's drug industry.…
Impact: One of the nine companies whose chairs signed the letter seeking faster trials, IP protections and fiscal flexibility in Europe. The move highlights its stake in European research and development competitiveness.
Sep 22, 2026 · 6 articles
6 30
International
Impact: Roche is expanding its output in North Carolina as part of the Swiss investment surge.
Jun 07, 2026 · 7 articles
8 20
Accidents
Impact: Roche is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
4 -20
Regulatory
Biopharmaceutical, a wholly-owned subsidiary of Biocon, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Union — European Medicines Agency issued a positive opinion recommending marketing authorisation for its Pertuzumab…
Impact: Markets the reference biologic Perjeta, which recorded over $3.6 billion in 2025 sales; the biosimilar approval threatens future revenue erosion from European competition.
Sep 21, 2026 · 7 articles
4 15
Regulatory
Impact: Roche, parent of F. Hoffmann-La Roche — Genentech, stands to benefit from expanded use of Tecentriq in MIBC, potentially increasing drug sales.
Aug 05, 2026 · 7 articles
2 20
Business
Impact: Roche, as parent of F. Hoffmann-La Roche — Genentech, benefits indirectly from the partnership through F. Hoffmann-La Roche — Genentech's enhanced cell therapy development capabilities. The impact on Roche is modest.
Jul 21, 2026 · 6 articles
+ 39 more events View on Dashboard
ERGEN INTELLIGENCE
Track Roche live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.